56 related articles for article (PubMed ID: 21156237)
1. EGFR expression and gene copy number in triple-negative breast carcinoma.
Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
[TBL] [Abstract][Full Text] [Related]
2. Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach.
Mudgal S; Paul P; Ravi B; Agrawal S; Kalra A; Rao S; Chowdhury N
Cureus; 2023 Sep; 15(9):e44785. PubMed ID: 37809181
[TBL] [Abstract][Full Text] [Related]
3. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.
Costa R; Shah AN; Santa-Maria CA; Cruz MR; Mahalingam D; Carneiro BA; Chae YK; Cristofanilli M; Gradishar WJ; Giles FJ
Cancer Treat Rev; 2017 Feb; 53():111-119. PubMed ID: 28104566
[TBL] [Abstract][Full Text] [Related]
4. Role of epidermal growth factor receptor in breast cancer.
Masuda H; Zhang D; Bartholomeusz C; Doihara H; Hortobagyi GN; Ueno NT
Breast Cancer Res Treat; 2012 Nov; 136(2):331-45. PubMed ID: 23073759
[TBL] [Abstract][Full Text] [Related]
5. Exploring the prognostic significance of arm-level copy number alterations in triple-negative breast cancer.
Doré S; Ali M; Sorin M; McDowell SAC; Desharnais L; Breton V; Yu MW; Arabzadeh A; Ryan MI; Milette S; Quail DF; Walsh LA
Oncogene; 2024 May; ():. PubMed ID: 38744952
[TBL] [Abstract][Full Text] [Related]
6. Three-Dimensional Cultivation a Valuable Tool for Modelling Canine Mammary Gland Tumour Behaviour In Vitro.
Huniadi M; Nosálová N; Almášiová V; Horňáková Ľ; Valenčáková A; Hudáková N; Cizkova D
Cells; 2024 Apr; 13(8):. PubMed ID: 38667310
[TBL] [Abstract][Full Text] [Related]
7. Navigating the Blood-Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases.
Terceiro LEL; Ikeogu NM; Lima MF; Edechi CA; Nickel BE; Fischer G; Leygue E; McManus KJ; Myal Y
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569410
[TBL] [Abstract][Full Text] [Related]
8. Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation.
Sagan OA; Rothstein A; Jambunathan B; Hadziahmetovic M; Antoniolli A; Rashid MH
Front Oncol; 2023; 13():1176868. PubMed ID: 37265791
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.
de Araújo RA; da Luz FAC; da Costa Marinho E; Nascimento CP; de Andrade Marques L; Delfino PFR; Antonioli RM; Araújo BJ; da Silva ACAL; Dos Reis Monteiro MLG; Neto MB; Silva MJB
Ecancermedicalscience; 2022; 16():1431. PubMed ID: 36158981
[TBL] [Abstract][Full Text] [Related]
10. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC.
Liu S; Polsdofer EV; Zhou L; Ruan S; Lyu H; Hou D; Liu H; Thor AD; He Z; Liu B
Mol Ther Oncolytics; 2021 Jun; 21():303-314. PubMed ID: 34141868
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics.
Jahan S; Karim ME; Chowdhury EH
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33530291
[TBL] [Abstract][Full Text] [Related]
13. Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment.
da Silva JL; Rodrigues FR; de Mesquita GG; Fernandes PV; Thuler LCS; de Melo AC
Breast Cancer (Dove Med Press); 2021; 13():31-44. PubMed ID: 33469357
[TBL] [Abstract][Full Text] [Related]
14. Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.
Herrera Juarez M; Tolosa Ortega P; Sanchez de Torre A; Ciruelos Gil E
Breast Care (Basel); 2020 Jun; 15(3):208-216. PubMed ID: 32774214
[TBL] [Abstract][Full Text] [Related]
15.
Jouali F; El Ansari FZ; Marchoudi N; Barakat A; Zmaimita H; Samlali H; Fekkak J
Int J Mol Epidemiol Genet; 2020; 11(1):16-25. PubMed ID: 32714499
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
Zecchin D; Moore C; Michailidis F; Horswell S; Rana S; Howell M; Downward J
EMBO Mol Med; 2020 Aug; 12(8):e11987. PubMed ID: 32672423
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (
Zakaria Z; Zulkifle MF; Wan Hasan WAN; Azhari AK; Abdul Raub SH; Eswaran J; Soundararajan M; Syed Husain SNA
Onco Targets Ther; 2019; 12():7749-7756. PubMed ID: 31571924
[TBL] [Abstract][Full Text] [Related]
18. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
19. Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs.
Zhang Y; Li J; Lai XN; Jiao XQ; Xiong JP; Xiong LX
Cells; 2019 Feb; 8(2):. PubMed ID: 30754684
[TBL] [Abstract][Full Text] [Related]
20. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
Ahmed TA; Adamopoulos C; Karoulia Z; Wu X; Sachidanandam R; Aaronson SA; Poulikakos PI
Cell Rep; 2019 Jan; 26(1):65-78.e5. PubMed ID: 30605687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
